Raymond James Trust N.A. Grows Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Raymond James Trust N.A. grew its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 40.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,131 shares of the company's stock after acquiring an additional 9,185 shares during the period. Raymond James Trust N.A.'s holdings in GE HealthCare Technologies were worth $3,016,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Quent Capital LLC lifted its position in GE HealthCare Technologies by 18.4% during the third quarter. Quent Capital LLC now owns 766 shares of the company's stock valued at $72,000 after purchasing an additional 119 shares during the period. Greenleaf Trust lifted its holdings in GE HealthCare Technologies by 1.7% in the third quarter. Greenleaf Trust now owns 7,619 shares of the company's stock valued at $715,000 after acquiring an additional 124 shares during the period. EverSource Wealth Advisors LLC boosted its position in GE HealthCare Technologies by 8.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company's stock worth $135,000 after purchasing an additional 127 shares in the last quarter. Quarry LP increased its holdings in shares of GE HealthCare Technologies by 28.3% during the 2nd quarter. Quarry LP now owns 594 shares of the company's stock valued at $46,000 after purchasing an additional 131 shares in the last quarter. Finally, Harbour Investments Inc. lifted its stake in shares of GE HealthCare Technologies by 4.3% in the 3rd quarter. Harbour Investments Inc. now owns 3,164 shares of the company's stock valued at $297,000 after purchasing an additional 131 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on GEHC. UBS Group lowered shares of GE HealthCare Technologies from a "neutral" rating to a "sell" rating and dropped their price target for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. Wells Fargo & Company raised their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an "overweight" rating in a research report on Thursday, October 31st. Stifel Nicolaus upped their price target on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a "buy" rating in a report on Monday, September 30th. Evercore ISI increased their price target on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, BTIG Research upgraded GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.36.

GE HealthCare Technologies Price Performance

GEHC traded up $0.44 on Friday, hitting $82.44. 5,934,944 shares of the company's stock were exchanged, compared to its average volume of 3,795,040. GE HealthCare Technologies Inc. has a fifty-two week low of $66.39 and a fifty-two week high of $94.55. The stock has a market cap of $37.66 billion, a price-to-earnings ratio of 22.65, a P/E/G ratio of 2.94 and a beta of 1.24. The firm has a 50-day moving average price of $88.35 and a 200-day moving average price of $83.60. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $1.06 by $0.08. The firm had revenue of $4.86 billion for the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. GE HealthCare Technologies's quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the business posted $0.99 earnings per share. As a group, equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.29 earnings per share for the current year.

GE HealthCare Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Friday, October 18th were given a dividend of $0.03 per share. The ex-dividend date of this dividend was Friday, October 18th. This represents a $0.12 dividend on an annualized basis and a yield of 0.15%. GE HealthCare Technologies's payout ratio is 3.30%.

Insiders Place Their Bets

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the transaction, the chief executive officer now directly owns 24,298 shares of the company's stock, valued at $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.